Takeda Chemical Industries, Inc.

Takeda Chemical Company, Ltd.

Tetsuya Aono

Shigenori Ohkawa

Takayuki Doi

Masahiro Suno

Go Kito

Kiyohisa Kawai

Shunsaku Noguchi

Yoshiaki Araki

Koichi Matsumura

Fumio Itoh

Masuo Yamaoka

Keizo Inoue

Hiroaki Nomura

Shoji Kishimoto

Seiichi Tanida

Tomohiro Kaku

Yasuhiko Kawano

Shogo Marui

Masafumi Nakao

Koichi Yukishige

Seiji Kuzuna

Katsutoshi Mizuno

Fused ring compounds, process for producing the same and use thereof

Disclosed are intermediates for the preparation of novel aminocoumaran derivatives of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are a hydrogen atom, an acyl group, an alkoxycarbonyl group, an aliphatic group or aromatic group; R.sup.3, R.sup.4 and R.sup.5 are an optionally acylated hydroxyl, optionally substituted amino group, alkoxy group or aliphatic group, or two of R.sup.3, R.sup.4 and R.sup.5 may be linked together to form a carbocyclic group; R.sup.6 and R.sup.7 are an aliphatic group and at least one of them has a methylene group at the .alpha.-position; R.sup.8 and R.sup.9 are a hydrogen atom or an aliphatic group or aromatic group, or a salt thereof is useful for medicines for preventing and treating various diseases such as arterial sclerosis, hepatopathy, cerebrovascular diseases and the like.

Intermediates for the preparation of aminocoumaran derivatives

Heterocyclic compounds, their production and use

A novel aminocoumaran derivative of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are a hydrogen atom, an acyl group, an alkoxycarbonyl group, an aliphatic group or aromatic group; R.sup.3, R.sup.4 and R.sup.5 are an optionally acylated hydroxyl optionally substituted amino group, alkoxy group or aliphatic group, or two of R.sup.3, R.sup.4 and R.sup.5 may be linked together to form a carbocyclic group; R.sup.6 and R.sup.7 are an aliphatic group and at least one of them has a methylene group at the .alpha.-position; R.sup.8 and R.sup.9 are a hydrogen atom or an aliphatic group or aromatic group, or a salt thereof is useful for medicines for preventing and treating various diseases such as arterial sclerosis, hepatopathy, cerebrovascular diseases and the like.

Intermediates for pharmaceutically useful aminocoumaran derivatives

A compound of the invention is represented by the formula: ##STR1## wherein R.sup.1 and R.sup.2 are the same or different, an acyl group; R.sup.3, R.sup.4, R.sup.6 and R.sup.7 are the same or different, hydrogen or an alkyl group; R.sup.5 is hydrogen, an alkyl group or a hydroxyl group which may optionally be protected, or R.sup.4 and R.sup.5 are combined to form a chemical bond; X is a carbonyl group or a sulfonyl group; Y is an amino acid sequence consisting of 1 to 7 amino acid residues which may optionally be protected and having optionally an intervening --SO.sub.2 NH--; n is an integer of 0 to 2, or a salt thereof. The compound or salt thereof of the present invention possesses immunoenhancing activity and platelet reduction recovery activity, and can be used as a prophylactic/therapeutic agent for leukocytopenia in cancer chemotherapy or radiotherapy, as an immunoenhancing agent in bone marrow transplantation therapy and the treatment of osteomyelodysplasia and aplastic anemia, and as a prophylactic/therapeutic agent for thrombocytopenia.

Thioglycerol derivatives

A novel aminocoumaran derivatives of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are a hydrogen atom, an acyl group, an alkoxycarbonyl group, an aliphatic group or aromatic group; R.sup.3, R.sup.4 and R.sup.5 are an optionally acylated hydroxyl optionally substituted amino group, alkoxy group or aliphatic group, or two of R.sup.3, R.sup.4 and R.sup.5 may be linked together to form a carbocyclic group; R.sup.6 and R.sup.7 are an aliphatic group and at least: one of them has a methylene group at the .alpha.-position; R.sup.8 and R.sup.9 are a hydrogen atom or an aliphatic group or aromatic group, or a salt thereof is useful for medicines for treating various diseases such as arterial sclerosis, hepatopathy, cerebrovascular diseases and the like.

Method of using aminocoumaran derivatives for treating cerebrovascular

A novel aminocoumaran derivatives of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are a hydrogen atom, an acyl group, an alkoxycarbonyl group, an aliphatic group or aromatic group; R.sup.3 R.sup.4 and R.sup.5 are an optionally acylated hydroxyl optionally substituted amino group, alkoxy group or aliphatic group, or two of R.sup.3, R.sup.4 and R.sup.5 may be linked together to form a carbocyclic group; R.sup.6 and R.sup.7 are an aliphatic group and at least one of them has a methylene group at the .alpha.-position; R.sup.8 and R.sup.9 are a hydrogen atom or an aliphatic group or aromatic group, or a salt thereof is useful for medicines for preventing and treating various diseases such as arterial schleosis, hepatopathy, cerebrovascular diseases and the like.

Aminocoumaran derivatives, their production and use

New thiazolo[5,4-b]azepine compounds represented by ##STR1## wherein R.sup.1 is a hydrogen atom, an aliphatic group which may be substituted, a carboxylic acyl group which may be substituted or a sulfonic acyl group which may be substituted; R.sup.2 is a hydrogen atom, an aromatic group which may be substituted or an aliphatic group which may be substituted, which are capable of e.g., inhibiting lipoperoxide formation.

Thiazolo [5,4-b]azepine compounds

A novel condensed thiazole derivative of the formula [I]: ##STR1## wherein A is a single bond or CH.sub.2 ; R.sup.1 is hydrogen atom, or an optionally substituted aliphatic, carboxylic acyl or sulfonic acyl group; and R.sup.2 is hydrogen atom, or an optionally substituted aromatic cyclic or aliphatic group, or a salt thereof. The compound [I] is useful for medicines for preventing and treating various diseases such as cancer, arterial sclerosis, hepatopathy, cerebrovascular diseases, inflammatory and the like. A process of the compound of the formula [I] or a salt thereof and a pharmaceutical composition comprising the compound of the formula [I] or a pharmaceutically acceptable salt thereof as an active component are also disclosed.

Condensed thiazole compounds and use as pharmaceuticals

Thiazolo[5,4-b]azepine compounds

Thiazolo (5,4-B)azepine compounds

A novel chromone derivative having a strong antitumor activity of the general formula: ##STR1## wherein R.sup.1 is an unsaturated alkyl or cycloalkyl group having 3 to 7 carbon atoms; R.sup.2 is hydrogen atom or a halogen atom; R.sup.3 is hydrogen atom or a lower alkyl group; and X is carboxyl group, or its salt, ester or amide.

Chromone derivatives useful as antitumor agents

A compound of the general formula [I]: ##STR1## wherein R.sub.1 represents a higher alkyl group or an N-(higher alkyl)carbamoyl group, R.sub.2 represents a lower alkyl group, an acyl group having at least three carbon atoms, an N-(lower alkyl)carbamoyl group, an N-(lower alkyl)thiocarbamoyl group or a benzyl group, R represents a primary, secondary or tertiary amino group or a quaternary ammonium group, x is 1 or 2, y is a number of 0, 1 or 2, and z is an integer of 2-10, or a pharmaceutically acceptable salt thereof. The novel substances have both anti-tumor activity and platelet activating factor-inhibiting property, and they are effective as an anti-tumor agent without circulatory trouble.

Nitrogen- and sulfur-containing lipid compounds their production and use

A process is disclosed for production of a sugar ketal, which comprises reacting a sugar with a ketone in the presence of hydrogen iodide. The formation of unfavorable by-products can be reduced to a trace amount. The process offers the objective ketal in improved yields, and an industrially advantageous process.

Process for production of sugar ketals

A process is disclosed for production of a sugar ketal, which comprises reacting a sugar with a ketone in the presence of (A) (1) copper, or an oxide, hydroxide or salt thereof and (2) hydrogen chloride or hydrogen bromide, or (B) cupric chloride or cupric bromide, said catalyst system being very effective in a small amount. The formation of unfavorable by-products can be reduced to a trace amount. The process offers the objective ketal in improved yields, and an industrially advantageous process.

Growing community of inventors

Nagaokakyo, Japan

Tetsuya Aono